Brief: Diaxonhit enrolls 1000th patient in DX15 study
14/12/2015 16:42
Dec 14 (Reuters) - Diaxonhit SA ALEHT.PA :
* Announces enrollment of the 1000th patient in the
validation study of the performance of molecular test DX15 in
thyroid cancer
Source text for Eikon: ID:nHUGbtCkFp
Further company coverage: ALEHT.PA
(Gdynia Newsroom:)
((Gdynia.newsroom@thomsonreuters.com; +48 58 698 39 20;))
Recent news on Eurobio Scientific SA
See all newsBrief: Eurobio Scientific EB Development Files Public Offer For Shares
Brief: Eurobio Scientific Says At End Of June 2024, Recorded Revenues Of 73.4 Mln Euros, Compared With 59.1 Mln Euros A Year Ago
Brief: Eurobio Scientific FY Core Business Revenues Up At EUR 130 Mln
Brief: Eurobio Scientific Cancels 694,300 Treasury Shares, Representing Around 6.34% Of Share Capital
Brief: Eurobio Scientific H1 Ebitda Up To EUR 13.4 Million